ArticleClinical and experimental nephrology2025
Construction of arginine vasopressin receptor 2-deficient rats by the rGONAD method.
Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical and genetic analysis of X-linked nephrogenic diabetes insipidus caused by a novelIntractable & rare diseases research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCongenital nephrogenic diabetes insipidus (NDI) is a hereditary disease characterized by a reduced response to arginine vasopressin in the renal collecting duct. NDI is primarily caused by mutations in the arginine vasopressin receptor 2 (AVPR2). Several animal models have been developed for congenital NDI; however, the appropriate models are limited. Thus, we constructed a novel Avpr2-deficient rat model using gene-editing technology to study the pathophysiological mechanisms of NDI.
methodsAvpr2-deficient rats were generated via a novel genome editing approach termed the rat Genome-editing via Oviductal Nucleic Acid Delivery (rGONAD) method. The phenotypes were analyzed using biological, molecular, and histological examinations. The effects of hydrochlorothiazide (40 mg/kg/d) on 24-h water intake, urine volume, and urine osmolality were evaluated in a metabolic cage.
resultsAvpr2-deficient rats were born and weaned under normal rearing conditions and exhibited symptoms similar to those of human congenital NDI, such as polydipsia, polyuria, and growth retardation. Although they exhibited hydronephrosis-like kidneys, no glomerular or tubular damage was observed. Aquaporin-2 was retained in the cytoplasm of collecting duct cells, and its phosphorylation was suppressed. Administration of hydrochlorothiazide decreased urine volume and improved urine osmolality in Avpr2-deficient rats.
conclusionsAvpr2-deficient rats are a reliable model of congenital NDI for elucidating the underlying mechanisms and identifying therapeutic targets.
Indexed as
Identifiers
40102322What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.